COMMUNIQUÉS West-GlobeNewswire

Teva Expands European biosimilars portfolio with launch of AHZANTIVE® (aflibercept) biosimilar to Eylea®
04/06/2026
AHZANTIVE ® (aflibercept) is an EMA-approved biosimilar to Eylea ® (aflibercept) with demonstrated similarity in efficacy, safety and immunogenicity to the reference product The launch expands Teva’s biosimilars [...]
Emergent BioSolutions Supports Victoria’s Voice Foundation’s National Naloxone Awareness Day to Help Save Lives from Opioid Overdose
04/06/2026
Efforts focus on increasing awareness, expanding access to lifesaving NARCAN® Nasal Spray and reaching more communities with educational initiatives and resources GAITHERSBURG, Md., June 04, 2026 (GLOBE NEWSWIRE) -- In [...]
Noom Members Kept Losing Weight a Full Year After the Program Ended, Largest-Ever Noom Randomized Clinical Trial Shows
04/06/2026
Peer-reviewed randomized controlled trial of 427 adults found that after completing Noom’s 16-week program, members continued losing weight for the next 52 weeks — reaching an average 4.1% body weight loss by week 68. [...]
Immutep to Present Positive Interim Phase I Data for IMP761, a First-in-Class LAG-3 Agonist Antibody, at EULAR 2026
04/06/2026
First-in-human Phase I study met its primary endpoint, demonstrating favourable safety and tolerability in healthy volunteers in the single ascending dose part of the study Phase I data demonstrate statistically [...]
Daré Bioscience Announces the Upcoming Launch of Flora Sync LF5™ Vaginal Probiotic Capsules
04/06/2026
First Product Revenue Expected This Month, Opening New Commercial Chapter for Women's Health Innovator Limited-Time Launch Offer: 30% Off + Free Shipping SAN DIEGO, June 04, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc [...]
Arvinas Joins The Michael J. Fox Foundation’s LITE and PPMI Programs to Advance New Therapies Targeting LRRK2 for Parkinson’s Disease
04/06/2026
NEW HAVEN, Conn., June 04, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced it has recently joined the [...]
Melanoma Research Alliance Appoints Stephanie Kauffman as Chief Executive Officer
04/06/2026
WASHINGTON, June 04, 2026 (GLOBE NEWSWIRE) -- The Melanoma Research Alliance (MRA), the world's leading nonprofit funder of melanoma research, today announced the appointment of Stephanie Kauffman as Chief Executive [...]
Pure Harvest Corporate Group (OTC: PHCG), Operating as Mixie Technologies, Announces HoloTwin 2.0 Framework for Large-Scale 3D Visualization in the Browser
04/06/2026
With the coming HT Scan capture app, HoloTwin 2.0 forms an end-to-end platform for creating digital twins of buildings and campuses and sharing them across an organization in a standard web browser DENVER, June 04, 2026 [...]
IMUNON Announces Up to $10 Million Cash Financing
04/06/2026
Includes up-front issuance of preferred stock for $2.5 million and secured promissory notes for $7.72 million Uniquely structured, flexible financing supports IMUNON’s Highly Anticipated Phase 3 OVATION 3 Study of IMNN- [...]
Amneal Announces U.S. FDA Approval of Romidepsin Injection Solution
04/06/2026
Ready-to-use romidepsin formulation; offers a more convenient alternative to lyophilized powder requiring reconstitution Competitive Generic Therapy approval provides 180 days of market exclusivity and further expands [...]
NXTC Announces Replay Available for Virtual KOL Event Discussing ASCO 2026 Dose Escalation Data from Phase 1 Trial of SIM0505 for Gynecologic Cancers
04/06/2026
BELTSVILLE, Md., June 04, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel therapies to treat cancer, today announced the [...]
Drew Brees Collaborates with ARS Pharmaceuticals to Raise Awareness About Living Life with Severe Allergies
04/06/2026
Former NFL quarterback and 2026 Hall of Fame inductee highlights daily life for people living with severe food allergies and role preparedness plays in living fully Collaboration focuses on education around the [...]
Celularity and Fountain Life Announce Availability of Cenplacel-L for Investigational Use Under New Florida Law, Establishing Scalable Pathway for Advancement of Placental-Derived Cell Therapies
04/06/2026
FLORHAM PARK, N.J. and ORLANDO, Fla., June 04, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a longevity-focused regenerative and cellular medicine company pioneering placental-derived cellular [...]
Weight Watchers to Increase Access to Comprehensive Weight Loss Options for Patients Nationwide through LillyDirect
04/06/2026
LillyDirect customers can now connect to Weight Watchers Med+ program, an integrated GLP-1 access and care model, driving greater weight loss results than medication alone NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- WW [...]
Novartis IgAN data in The Lancet show clinically meaningful slowing of kidney function decline with Vanrafia® over 2.5 years
04/06/2026
Phase III ALIGN study results showed reduced rate of kidney function decline by ~34% with Vanrafia vs placebo, based on supportive eGFR slope analysis 1 Vanrafia reduced protein in urine by 38.3% vs placebo at 9 months [...]
Press Release: Sanofi launches 2026 global employee stock purchase plan
04/06/2026
Sanofi launches 2026 global employee stock purchase plan Paris, June 4, 2026. Sanofi’s global employee shareholder plan, Action 2026, opens on June 9, 2026, to around 75,000 employees in 52 countries. Now in its 12th [...]
Communiqué de presse : Sanofi lance son plan mondial 2026 d’actionnariat salarié
04/06/2026
Sanofi lance son plan mondial 2026 d’actionnariat salarié Paris, le 4 juin 202 6 . Sanofi lance Action 2026, son plan mondial d’actionnariat salarié, qui sera ouvert le 9 juin 2026 à plus de 75 000 salariés dans 52 pays [...]
WellSpan Health and Philips Announce Landmark Strategic Alliance, Accelerating Innovation and Research Across Central Pennsylvania and Northern Maryland
04/06/2026
June 4, 2026 Seven-year collaboration puts WellSpan at the forefront of diagnostics and imaging in community health through a groundbreaking research and innovation strategy aimed at shaping the future of care delivery [...]
Alvotech announces resubmission of U.S. Biologics License Applications for AVT05, a proposed biosimilar to Simponi® and Simponi Aria®, and AVT06, a proposed biosimilar to Eylea®
04/06/2026
REYKJAVIK, Iceland, June 04, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, [...]

Pages